Navigation Links
AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
Date:5/5/2009

REDWOOD CITY, Calif., May 5 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced that it has initiated a Phase 2 clinical trial of its ARX-01 Sufentanil NanoTab(TM) PCA System, a proprietary drug/device combination product candidate being developed for management of acute post-operative pain in the hospital setting. The primary objective of this open-label study is to assess the functionality of the ARX-01 System for post-operative pain management in patients undergoing unilateral knee replacement surgery.

AcelRx Chief Executive Officer, Thomas Schreck, commented, "We have successfully completed two placebo-controlled Phase 2 studies evaluating the efficacy and safety of Sufentanil NanoTabs in knee replacement and major abdominal surgery patients. Now with this third Phase 2 study we are validating the functionality of the handheld component of the ARX-01 Sufentanil NanoTab PCA System as we advance the ARX-01 clinical program."

Study investigator David Griffin, MD, of the Orthopaedic Center of Vero Beach, Florida stated, "I am excited about ARX-01; I believe it has the potential to address a large unmet medical need in the management of post-operative pain by allowing patients to manage their pain without the need for an IV line or complicated IV PCA pumps. Seeing the smooth, uneventful initiation of this first study utilizing the ARX-01 Sufentanil PCA System adds to the already compelling Phase 2 data that AcelRx announced in December."

About Acute Post-Operative Pain

Annually, approximately 8 million patients in the U.S. receive intravenous (IV) patient-controlled analgesia (PCA), typically utilizing morphine, for inpatient post-operative pain, with a similar number in the E.U. Despite its widespread use, the IV PCA architecture has several limitations. The IV line tethering the patient to the PCA pump discourages mobility, which is a critical factor in preventing post-operative c
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
3. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
4. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
5. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
6. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
7. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
8. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
9. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
10. Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma
11. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 Remedy Informatics, a ... and life sciences research, today announced it has ... IT Schedule 70 supply contract (GS-35F-367AA, effective May ... innovative IT solutions to government agencies at federal, ... contract, Remedy has placed its products and services ...
(Date:6/18/2013)... INDIANAPOLIS , June 18, 2013   ... partnership with Aegis Health Group to ... Aegis workforce wellness programs administered by health systems ... system, manufactured by PTS and distributed through ... for total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, ...
(Date:6/17/2013)... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... a preliminary prospectus supplement to its effective shelf registration statement ... with securities regulatory authorities in each of the provinces of ... offering of its common shares to raise gross proceeds of ... also grant to the underwriters of the Offering an option, ...
Breaking Medicine Technology:Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4
... For More Women to ... Participate in Clinical Trials, ORLANDO, ... women remain a significant minority in,cardiovascular randomized controlled trials funded ... Author, Esther S.H. Kim, M.D., M.P.H., Senior Author Venu Menon,M.D., ...
... N.J., Nov. 5 CANTEL MEDICAL,CORP. (NYSE: ... from schools for its hand sanitization and surface ... MRSA,(Methicillin-resistant Staphylococcus aureus) skin infections. According to ... "We are,in contact with numerous school officials helping ...
Cached Medicine Technology:Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates 2Cantel Medical Corp.'s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products 2Cantel Medical Corp.'s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products 3
(Date:6/18/2013)... 2013 Two months ago, Suyima Torres, 28, ... for a second session of a silicone treatment for gluteus ... treatment was allegedly performed by a mystery Venezuelan doctor in ... According to Dr. Bernabe Vazquez of Bayshore Cosmetic Surgery ... from doctor’s who are not board certified is more common ...
(Date:6/18/2013)... Calif. (PRWEB) June 18, 2013 David ... professor of Family Medicine for the College of Osteopathic ... Health Sciences has been elected president of the ... Edmund G. Brown Jr. appointed Connett, a 1984 alumnus ... OMBC members recently elected Connett to the position during ...
(Date:6/18/2013)... to keep their scheduled medical appointments and their ... listens, explains things clearly and knows them as a ... suggests. , "If people feel their doctor really knows ... has their best interests at heart and may be ... Tabor E. Flickinger, M.D., M.P.H., a fellow in the ...
(Date:6/18/2013)... 2013)-- An international team of investigators co-led by Weill ... evidence-based surgery and device research, similar to the kind ... , "Currently, there is no dynamic research framework to ... benefits to patients or may even be harmful," says ... College. , In the June 18 issue of ...
(Date:6/18/2013)... Two weeks ago, eyes across America were glued to ... reported by CNN on June 6 in an article ... building scheduled to be demolished ended up burying a group ... persons succumbed to their injuries. It was a sad ... should serve as a reminder that the safety of Pennsylvania ...
Breaking Medicine News(10 mins):Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3Health News:Respect may be the key to stopping patient 'no shows' 2Health News:Tackling a framework for surgical innovation 2Health News:Tackling a framework for surgical innovation 3Health News:Ensuring The Safety of Pennsylvania Worksites 2Health News:Ensuring The Safety of Pennsylvania Worksites 3
... study involving 38 populations across 21 countries, reserachers have found ... ,"Blood pressure did not go down in all ... them," said Prof Tunstall-Pedoe, who led the World Health Organization ... was not great, but it did appear to have a ...
... has a connection with obesity risks as they grow up, more so, ... ,A team of researchers led by Sarah E. Anderson, M.S., from Tufts ... women and 417 men - who underwent assessment four times between 1983 ... 18 during the beginning of the study, and were in the age ...
... that India is crowned as the diabetic capital. Hence he ... for prevention and control of cardiovascular disease, //stroke and diabetes. ... ,He submitted a draft of the programme to the ... it workable. ,The programme’s main aim is ...
... Calcium supplementation during pregnancy can reduce the incidence ... a study published by American Journal of Obstetrics ... characterized by elevated blood pressure and proteinuria (high ... the feet, hands and legs is usually seen. ...
... known for a long time that smoking is associated with ... and emphysema. A new study has highlighted that smoker’s children// ... cause pneumonia, sinusitis and meningitis. ,Nothing, not even ... to help people quit smoking. Let us hope that this ...
... pertaining to dental health a common concern is fluoride ... teeth.//, ,This is a revelation of several studies ... Research's annual meeting from March 8, 2006, in Orlando, ... mentioned. ,An Iowa Fluoride Study which followed ...
Cached Medicine News:
For the quantitative determination of Creatine Kinase in serum....
For the quantitative determination of creatine kinase-MB in serum. Kinetic Reaction measured at 340 nm. Linearity: 700 IU/L at 37C....
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of total glucose in human serum....
Medicine Products: